Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Blinatumomab with De-Escalated Chemotherapy for Infant KMT2A -Rearranged B-Cell Acute Lymphoblastic Leukemia

Blood (2024) 144 (Supplement 1): 2816.

https://doi.org/10.1182/blood-2024-205461

Published: 2024

Journal Articles

Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia

Blood (2022) 140 (Supplement 1): 3268–3270.

https://doi.org/10.1182/blood-2022-162565

Published: 2022

Journal Articles

Blinatumomab As Toxicity Sparing First Line Treatment of Children and Young Persons with B-Precursor Acute Lymphoblastic Leukaemia (B-ALL)

Blood (2022) 140 (Supplement 1): 8987–8988.

https://doi.org/10.1182/blood-2022-162475

Published: 2022

Journal Articles

Systematic Intention to Treat Analysis of Real-World Outcomes in Children and Young Adults Receiving Tisagenlecleucel: From Elegibility through Treatment Failure

Blood (2022) 140 (Supplement 1): 2408–2410.

https://doi.org/10.1182/blood-2022-162863

Published: 2022

Journal Articles

Intention to Treat Analysis of Real-World Outcomes Following Tisgenlecleucel Therapy for Pediatric and Young Adult ALL through a National Access Programme

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-138438

Published: 2020

Journal Articles

Blinatumomab for infant acute lymphoblastic leukemia

Katherine Clesham, Vasudha Rao, Jack Bartram, Philip Ancliff, Sara Ghorashian, David O’Connor, Vesna Pavasovic, Anupama Rao, Sujith Samarasinghe, Michelle Cummins, Andrea Malone, Katharine Patrick, Denise Bonney, Beki James, Brenda Gibson, Ajay Vora

Blood (2020) 135 (17): 1501–1504.

https://doi.org/10.1182/blood.2019004008

Published: 2020

Journal Articles

EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications

Claire Schwab, Sarra L. Ryan, Lucy Chilton, Alannah Elliott, James Murray, Stacey Richardson, Christopher Wragg, John Moppett, Michelle Cummins, Oliver Tunstall, Catriona A. Parker, Vaskar Saha, Nicholas Goulden, Ajay Vora, Anthony V. Moorman, Christine J. Harrison

Blood (2016) 127 (18): 2214–2218.

https://doi.org/10.1182/blood-2015-09-670166

Published: 2016

Includes: Supplemental data

Journal Articles

Allogeneic Stem Cell Transplantation for Refractory Acute Myeloid Leukemia in Pediatric Patients: The UK Experience

Patricia M O'Hare, Giovanna Lucchini, Michelle Cummins, Paul Veys, Mike Potter, Sarah Lawson, Ajay J. Vora, Robert Wynn, Andrew Peniket, Keiren Kirkland, Rachel Pearce, Julia Perry, Persis Jal Amrolia

Blood (2015) 126 (23): 4404.

https://doi.org/10.1182/blood.V126.23.4404.4404

Published: 2015

Journal Articles

Vaccination - a Novel Strategy to Improve the Persistence of CD19CAR Transduced T-Cells in Relapsed Paediatric ALL: Preliminary Results from the CD19TPALL Study

Martin Pule, Sara Ghorashian, MD PhD FRCPath, Laura Clifton-Hadley, PhDBSc, Paul Smith, Soraya Saiagh, Paul Veys, FRCP,FRCPath, Nicholas Goulden, MD PhD, Gary Wright, Ettore Biagi, MD PhD, Bianca Altvater, PhD, Brigitte Dreno, MD, Kim Champion, PhD, Michelle Cummins, MD, Rachael Hough, MDBMBS,FRCP,FRCPath, Martin G. Sauer, MD, Claudia Rossig, MD, Persis Amrolia

Blood (2014) 124 (21): 383.

https://doi.org/10.1182/blood.V124.21.383.383

Published: 2014

Journal Articles

EBF1-PDGFRΒ Fusion in Paediatric Acute Lymphoblastic Leukaemia (ALL): Genetic Profile and Clinical Implications

Claire Schwab, Rebecca Andrews, Lucy Chilton, Alannah Elliott, Gerald Keil, Stacey Richardson, Sarra L. Ryan, Christopher Wragg, John Moppett, Michelle Cummins, MD, Nicholas Goulden, MD PhD, Ajay J. Vora, Anthony V. Moorman, Christine J. Harrison

Blood (2014) 124 (21): 1068.

https://doi.org/10.1182/blood.V124.21.1068.1068

Published: 2014

Journal Articles

Clofarabine/Cyclophosphamide/Etoposide Combination Chemotherapy Well Tolerated in An Infant with Refractory AML

Shahera Rahman, MBBS, Philip P Connor, FRCPath, John Moppett, PhD, FRCPath, Meriel Jenney, Michelle Cummins, Jackie Cornish

Blood (2008) 112 (11): 4020.

https://doi.org/10.1182/blood.V112.11.4020.4020

Published: 2008

NARROW

Blinatumomab with De-Escalated Chemotherapy for Infant KMT2A -Rearranged B-Cell Acute Lymphoblastic Leukemia

Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia

Blinatumomab As Toxicity Sparing First Line Treatment of Children and Young Persons with B-Precursor Acute Lymphoblastic Leukaemia (B-ALL)

Systematic Intention to Treat Analysis of Real-World Outcomes in Children and Young Adults Receiving Tisagenlecleucel: From Elegibility through Treatment Failure

Intention to Treat Analysis of Real-World Outcomes Following Tisgenlecleucel Therapy for Pediatric and Young Adult ALL through a National Access Programme

Blinatumomab for infant acute lymphoblastic leukemia

EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications

Allogeneic Stem Cell Transplantation for Refractory Acute Myeloid Leukemia in Pediatric Patients: The UK Experience

Vaccination - a Novel Strategy to Improve the Persistence of CD19CAR Transduced T-Cells in Relapsed Paediatric ALL: Preliminary Results from the CD19TPALL Study

EBF1-PDGFRΒ Fusion in Paediatric Acute Lymphoblastic Leukaemia (ALL): Genetic Profile and Clinical Implications

Clofarabine/Cyclophosphamide/Etoposide Combination Chemotherapy Well Tolerated in An Infant with Refractory AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only